Hellerup, Denmark, April 16, 2015. Azanta announces executive management change to support the company's strategy moving forward and to ensure a focused organization. As a result of the organizational restructuring, Chief Executive Officer, Dr. Claus Møller, has been released from his contract and is leaving the company.
Hanne Damgaard Jensen, Executive Vice President and Chief Development Officer has been promoted and appointed as new Chief Executive Officer. The reorganization reduces the executive management team and allows a dynamic organization with operational agility and short decision making.
Lars Aaen, Chairman of the Board of Azanta A/S, has the following comments to the change: "I would like to thank Claus Møller for his valuable contributions to Azanta's development and I wish him good luck in the future. I wish Hanne Damgaard Jensen success in taking the company forward and I look forward to working with her in her new role as CEO of Azanta A/S."
About Azanta A/S
Azanta A/S is a privately owned specialty pharma company primarily operating within oncology, women´s health and addiction medicine. The vision of Azanta A/S is to become an international market leader within specialty pharma products and innovative pharmaceutical products. Azanta A/S currently markets or makes available a string of specialty pharmaceutical products, including Nimoral, a hypoxic radiosensitizer for the treatment of head and neck cancer patients undergoing primary radiotherapy and Angusta for labour induction.
For further information, please visit www.azanta.com.
Hanne Damgaard Jensen - CEO
Tel: + 45 - 70 25 95 45
Fax: + 45 - 70 25 95 46